To date, the use of VEGF inhibitors has revolutionized the treatment of retinal diseases characterized by neovascularization, including AMD and DR, with many of these agents coming to represent new standards of care (Bakri et al., 2019; Framme et al., 2018; Singh et al., 2019; Tsilimbaris et al., 2016). This evidence concerns the gene VEGFA and Abnormal retinal morphology.